Cytochrome P450 in non-small cell lung cancer related to exogenous chemical metabolism

Frontiers in Bioscience - Scholar

Volumn 4 S, Issue 4, 2012, Pages 1539-1546

  Oyama, Tsunehiro ^a,b   Uramoto, Hidetaka ^c   Kagawa, Norio ^d   Yoshimatsu, Takashi ^e   Osaki, Toshihiro ^f   Nakanishi, Roichi ^g   Nagaya, Hisao ^b   Kaneko, Kazuhiro ^h   Muto, Manabu ⁱ   Kawamoto, Toshihiro ^c   Tanaka, Fumihiro ^c   Gotoh, Akinobu ^b  

^a Nishinihon Hospital   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e FUKUOKA WAJIRO HOSPITAL   (Japan)

^f ASO IIZUKA HOSPITAL   (Japan)

^g Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

^h NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

ⁱ KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anticancer drug; CYP19; CYP24; Cytochrome P450; Non small cell lung cancer; NSCLC

Indexed keywords

ANTIMETABOLITE; AROMATASE; AROMATASE INHIBITOR; BEVACIZUMAB; CISPLATIN; COLECALCIFEROL; CRIZOTINIB; CYCLOPHOSPHAMIDE; CYTOCHROME; CYTOCHROME P450; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IFOSFAMIDE; IRINOTECAN; NAVELBINE; PACLITAXEL; PEMETREXED; TSI; UFT; UNCLASSIFIED DRUG; VINCA ALKALOID; VINCRISTINE SULFATE; CARCINOGEN;

ARTICLE; DRUG METABOLISM; DRUG TARGETING; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; NONHUMAN; PROTEIN EXPRESSION; CHEMICALLY INDUCED DISORDER; DRUG DETOXIFICATION; ENZYMOLOGY; LUNG TUMOR; METABOLISM; PATHOLOGY; REVIEW;

CARCINOGENS; CARCINOMA, NON-SMALL-CELL LUNG; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; LUNG NEOPLASMS; METABOLIC DETOXICATION, DRUG;

EID: 84869426063     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s350     Document Type: Article

References (52)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu and M. J. Thun: Cancer statistics, 2009. CA Cancer J Clin, 59(4), 225-49 (2009))
2. E. Brambilla, W. D. Travis, T. V. Colby, B. Corrin and Y. Shimosato: The new World Health Organization classification of lung tumours. Eur Respir J, 18(6), 1059-68 (2001)) (Pubitemid 34092881)
3. D. S. Ettinger: Overview and state of the art in the management of lung cancer. Oncology (Williston Park), 18(7 Suppl 4), 3-9 (2004))
4. W. Zhang, W. D. Shannon, J. Duncan, G. L. Scheffer, R. J. Scheper and H. L. McLeod: Expression of drug pathway proteins is independent of tumour type. J Pathol, 209(2), 213-9 (2006)) (Pubitemid 43805417)
5. F. J. Gonzalez and H. V. Gelboin: Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev, 26(1-2), 165-83 (1994)) (Pubitemid 24171627)
6. K. F. Windmill, R. A. McKinnon, X. Zhu, A. Gaedigk, D. M. Grant and M. E. McManus: The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat Res, 376(1-2), 153-60 (1997)) (Pubitemid 27248598)
7. T. Oyama, K. Sugio, H. Uramoto, T. Kawamoto, N. Kagawa, S. Nadaf, D. Carbone and K. Yasumoto: Cytochrome P450 expression (CYP) in non-small cell lung cancer. Front Biosci, 12, 2299-308 (2007))
8. G. I. Murray: The role of cytochrome P450 in tumour development and progression and its potential in therapy. J Pathol, 192(4), 419-26 (2000))
9. T. Oyama, N. Kagawa, N. Kunugita, K. Kitagawa, M. Ogawa, T. Yamaguchi, R. Suzuki, T. Kinaga, Y. Yashima, S. Ozaki, T. Isse, Y. D. Kim, H. Kim and T. Kawamoto: Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front Biosci, 9, 1967-76 (2004)) (Pubitemid 38918646)
10. N. Gharavi and A. O. El-Kadi: Expression of cytochrome P450 in lung tumor. Curr Drug Metab, 5(2), 203-10 (2004)) (Pubitemid 38515248)
11. M. Czerwinski, T. L. McLemore, H. V. Gelboin and F. J. Gonzalez: Quantification of CYP2B7, CYP4B1, and CYPOR messenger RNAs in normal human lung and lung tumors. Cancer Res, 54(4), 1085-91 (1994)) (Pubitemid 24085467)
12. C. Toussaint, N. Albin, L. Massaad, D. Grunenwald, O. Parise, Jr., J. Morizet, A. Gouyette and G. G. Chabot: Main drug- and carcinogen-metabolizing enzyme systems in human non-small cell lung cancer and peritumoral tissues. Cancer Res, 53(19), 4608-12 (1993)) (Pubitemid 23304387)
13. J. T. Chang, H. Chang, P. H. Chen, S. L. Lin and P. Lin: Requirement of aryl hydrocarbon receptor overexpression for CYP1B1 up-regulation and cell growth in human lung adenocarcinomas. Clin Cancer Res, 13(1), 38-45 (2007)) (Pubitemid 46121850)
14. T. L. McLemore, S. Adelberg, M. C. Liu, N. A. McMahon, S. J. Yu, W. C. Hubbard, M. Czerwinski, T. G. Wood, R. Storeng, R. A. Lubet and et al.: Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst, 82(16), 1333-9 (1990))
15. S. D. Spivack, G. J. Hurteau, M. J. Fasco and L. S. Kaminsky: Phase I and II carcinogen metabolism gene expression in human lung tissue and tumors. Clin Cancer Res, 9(16 Pt 1), 6002-11 (2003)) (Pubitemid 38018087)
16. S. D. Spivack, G. J. Hurteau, A. A. Reilly, K. M. Aldous, X. Ding and L. S. Kaminsky: CYP1B1 expression in human lung. Drug Metab Dispos, 29(6), 916-22 (2001)) (Pubitemid 32488651)
17. P. Lin, H. Chang, W. L. Ho, M. H. Wu and J. M. Su: Association of aryl hydrocarbon receptor and cytochrome P4501B1 expressions in human non-small cell lung cancers. Lung Cancer, 42(3), 255-61 (2003)) (Pubitemid 37468537)
18. T. Fukami, M. Nakajima, I. Matsumoto, Y. Zen, M. Oda and T. Yokoi: Immunohistochemical analysis of CYP2A13 in various types of human lung cancers. Cancer Sci, 101(4), 1024-8 (2010))
19. H. Wang, W. Tan, B. Hao, X. Miao, G. Zhou, F. He and D. Lin: Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res, 63(22), 8057-61 (2003)) (Pubitemid 37466745)
20. H. Kushida, K. Fujita, A. Suzuki, M. Yamada, T. Endo, T. Nohmi and T. Kamataki: Metabolic activation of Nalkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase. Carcinogenesis, 21(6), 1227-32 (2000)) (Pubitemid 30389351)
21. E. Albano, P. Clot, M. Morimoto, A. Tomasi, M. Ingelman-Sundberg and S. W. French: Role of cytochrome P4502E1-dependent formation of hydroxyethyl free radical in the development of liver damage in rats intragastrically fed with ethanol. Hepatology, 23(1), 155-63 (1996)) (Pubitemid 26012104)
22. K. T. Kivisto, A. Linder, G. Friedel, P. Beaune, C. Belloc, H. K. Kroemer and P. Fritz: Immunohistochemical localization of cytochrome P450 2E1 in human pulmonary carcinoma and normal bronchial tissue. Virchows Arch, 426(3), 243-7 (1995))
23. H. Raunio, J. Hakkola, J. Hukkanen, O. Pelkonen, R. Edwards, A. Boobis and S. Anttila: Expression of xenobiotic-metabolizing cytochrome P450s in human pulmonary tissues. Arch Toxicol Suppl, 20, 465-9 (1998))
24. F. P. Guengerich: Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol, 39, 1-17 (1999)) (Pubitemid 29222549)
25. K. T. Kivisto, H. K. Kroemer and M. Eichelbaum: The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol, 40(6), 523-30 (1995)) (Pubitemid 26005556)
26. K. T. Kivisto, E. U. Griese, P. Fritz, A. Linder, J. Hakkola, H. Raunio, P. Beaune and H. K. Kroemer: Expression of cytochrome P 450 3A enzymes in human lung: a combined RT-PCR and immunohistochemical analysis of normal tissue and lung tumours. Naunyn Schmiedebergs Arch Pharmacol, 353(2), 207-12 (1996))
27. K. T. Kivisto, P. Fritz, A. Linder, G. Friedel, P. Beaune and H. K. Kroemer: Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue. Histochem Cell Biol, 103(1), 25-9 (1995))
28. S. Anttila, J. Hukkanen, J. Hakkola, T. Stjernvall, P. Beaune, R. J. Edwards, A. R. Boobis, O. Pelkonen and H. Raunio: Expression and localization of CYP3A4 and CYP3A5 in human lung. Am J Respir Cell Mol Biol, 16(3), 242-9 (1997)) (Pubitemid 127497446)
29. J. Hukkanen, O. Pelkonen, J. Hakkola and H. Raunio: Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit Rev Toxicol, 32(5), 391-411 (2002)) (Pubitemid 35191358)
30. T. Oyama, K. Sugio, T. Isse, A. Matsumoto, N. Nose, H. Uramoto, T. Nozoe, M. Morita, N. Kagawa, T. Osaki, M. Muto, K. Yasumoto and T. Kawamoto: Expression of cytochrome P450 in non-small cell lung cancer. Front Biosci, 13, 5787-93 (2008))
31. M. Tychopoulos, L. Corcos, P. Genne, P. Beaune and I. de Waziers: A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein. Cancer Gene Ther, 12(5), 497-508 (2005)) (Pubitemid 40629340)
32. A. M. Coscio and J. Garst: Lung cancer in women. Curr Oncol Rep, 8(4), 248-51 (2006)) (Pubitemid 43970975)
33. C. Patrone, T. N. Cassel, K. Pettersson, Y. S. Piao, G. Cheng, P. Ciana, A. Maggi, M. Warner, J. A. Gustafsson and M. Nord: Regulation of postnatal lung development and homeostasis by estrogen receptor beta. Mol Cell Biol, 23(23), 8542-52 (2003)) (Pubitemid 37441291)
34. R. J. Pietras, D. C. Marquez, H. W. Chen, E. Tsai, O. Weinberg and M. Fishbein: Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids, 70(5-7), 372-81 (2005)) (Pubitemid 40616035)
35. T. Oyama, M. Morita, T. Isse, N. Kagawa, S. Nakata, T. So, M. Mizukami, Y. Ichiki, K. Ono, M. Sugaya, H. Uramoto, T. Yoshimatsu, T. Hanagiri, K. Sugio, T. Kawamoto and K. Yasumoto: Immunohistochemical evaluation of cytochrome P450 (CYP) and p53 in breast cancer. Front Biosci, 10, 1156-61 (2005))
36. O. K. Weinberg, D. C. Marquez-Garban, M. C. Fishbein, L. Goodglick, H. J. Garban, S. M. Dubinett and R. J. Pietras: Aromatase inhibitors in human lung cancer therapy. Cancer Res, 65(24), 11287-91 (2005))
37. N. Kagawa, H. Hori, M. R. Waterman and S. Yoshioka: Characterization of stable human aromatase expressed in E. coli. Steroids, 69(4), 235-43 (2004)) (Pubitemid 38748719)
38. N. Kagawa: Efficient expression of human aromatase (CYP19) in E. coli. Methods Mol Biol, 705, 109-22 (2011))
39. W. C. Boon, J. D. Chow and E. R. Simpson: The multiple roles of estrogens and the enzyme aromatase. Prog Brain Res, 181, 209-32 (2010))
40. M. Demura, Y. Demura, S. Ameshima, T. Ishizaki, M. Sasaki, I. Miyamori, M. Yamagishi, Y. Takeda and S. E. Bulun: Changes in aromatase (CYP19) gene promoter usage in non-small cell lung cancer. Lung Cancer, 73(3), 289-93 (2011))
41. V. Mah, D. B. Seligson, A. Li, D. C. Marquez, Wistuba, II, Y. Elshimali, M. C. Fishbein, D. Chia, R. J. Pietras and L. Goodglick: Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res, 67(21), 10484-90 (2007))
42. D. C. Marquez-Garban, H. W. Chen, L. Goodglick, M. C. Fishbein and R. J. Pietras: Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann N Y Acad Sci, 1155, 194-205 (2009))
43. M. G. Anderson, M. Nakane, X. Ruan, P. E. Kroeger and J. R. Wu-Wong: Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol, 57(2), 234-40 (2006)) (Pubitemid 41779843)
44. R. A. Parise, M. J. Egorin, B. Kanterewicz, M. Taimi, M. Petkovich, A. M. Lew, S. S. Chuang, M. Nichols, T. El-Hefnawy and P. A. Hershberger: CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer, 119(8), 1819-28 (2006)) (Pubitemid 44356838)
45. N. Sawada, T. Sakaki, S. Kitanaka, S. Kato and K. Inouye: Structure-function analysis of CYP27B1 and CYP27A1. Studies on mutants from patients with vitamin D-dependent rickets type I (VDDR-I) and cerebrotendinous xanthomatosis (CTX). Eur J Biochem, 268(24), 6607-15 (2001)) (Pubitemid 34014768)
46. E. Uchida, N. Kagawa, T. Sakaki, N. Urushino, N. Sawada, M. Kamakura, M. Ohta, S. Kato and K. Inouye: Purification and characterization of mouse CYP27B1 overproduced by an Escherichia coli system coexpressing molecular chaperonins GroEL/ES. Biochem Biophys Res Commun, 323(2), 505-11 (2004)) (Pubitemid 39221126)
47. N. Urushino, K. Yamamoto, N. Kagawa, S. Ikushiro, M. Kamakura, S. Yamada, S. Kato, K. Inouye and T. Sakaki: Interaction between mitochondrial CYP27B1 and adrenodoxin: role of arginine 458 of mouse CYP27B1. Biochemistry, 45(14), 4405-12 (2006))
48. K. Yamamoto, E. Uchida, N. Urushino, T. Sakaki, N. Kagawa, N. Sawada, M. Kamakura, S. Kato, K. Inouye and S. Yamada: Identification of the amino acid residue of CYP27B1 responsible for binding of 25-hydroxyvitamin D3 whose mutation causes vitamin D-dependent rickets type 1. J Biol Chem, 280(34), 30511-6 (2005))
49. T. Sakaki, N. Kagawa, K. Yamamoto and K. Inouye: Metabolism of vitamin D3 by cytochromes P450. Front Biosci, 10, 119-34 (2005))
50. T. Sakaki, N. Sawada, K. Komai, S. Shiozawa, S. Yamada, K. Yamamoto, Y. Ohyama and K. Inouye: Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human CYP24. Eur J Biochem, 267(20), 6158-65 (2000))
51. T. Oyama, T. Mitsudomi, T. Kawamoto, A. Ogami, T. Osaki, Y. Kodama and K. Yasumoto: Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP1A1 genotypes in Japanese. Int Arch Occup Environ Health, 67(4), 253-6 (1995))
52. T. Oyama, T. Kawamoto, T. Mizoue, K. Nishida, T. Osaki, K. Sugio, K. Yasumoto and T. Mitsudomi: p53 mutations of lung cancer are not significantly affected by CYP1A1 or GSTM1 polymorphisms. Int J Oncol, 11, 305-309 (1997)) (Pubitemid 27305962)